

**ANNUAL GENERAL MEETING
OF ARGENX N.V. OF 26 APRIL 2017
AGENDA**

1. Opening
2. Report on the 2016 financial year (*discussion item*)
3. Explanation of the implementation of the remuneration policy in 2016 (*discussion item*)
4. Discussion and adoption of the 2016 annual report and annual accounts:
 - a. Discussion of the 2016 annual report (*discussion item*)
 - b. Adoption of the 2016 annual accounts (*voting item*)
 - c. Corporate governance statement (*discussion item*)
 - d. Allocation of losses of the Company in the financial year 2016 to the retained earnings of the Company (*voting item*)
 - e. Proposal to release the members of the board of directors from liability for their respective duties carried out in the financial year 2016 (*voting item*)
5. Appointment of A.A. Rosenberg as non-executive director to the board of directors of the Company (*voting item*)
6. Authorization of the board of directors to grant options pursuant to, and within the limits of, the argenx option plan, for a period of 18 months from the general meeting (*voting item*)
7. Conversion of the legal form of argenx N.V. into a European company limited by shares ("Societas Europaea") and relating amendment of the articles of association (and granting a proxy to each of the directors of the Company and each lawyer and (deputy) civil law notary of Freshfields Bruckhaus Deringer LLP, Amsterdam office, in having the deed of conversion and amendment executed) (*voting item*)
8. Authorization of the board of directors to issue additional shares in the share capital of the company up to a maximum of 20% of the outstanding share capital at the date of the general meeting (in addition to the authorizations under 6 and 9), for a period starting on the date of this general meeting and ending on 31 December 2017, for the purpose of a possible public offering of such shares in the United States (*voting item*)
9. Authorization of the board of directors to issue shares in the share capital of the Company up to a maximum of 20% of the outstanding capital at the date of the general meeting (in addition to the authorizations under 6 and 8), for a period of 18 months from the general meeting (*voting item*)
10. Authorization of the board of directors to limit or exclude pre-emptive rights with regard to an issuance of new shares and/or a grant of rights to subscribe for new shares pursuant to the authorization referred to under 6., 8. and 9. above for a period of 18 months from the general meeting (*voting item*)
11. Appointment of Deloitte Accountants B.V. for the 2017 financial year (*voting item*)
12. Any other business, announcements or questions
13. End of the annual general meeting